
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
10th Annual Gateway Conference to Virtually Showcase Leading Companies on September 8-9, 2021
Tue 24 Aug 21, 05:30 PMCannabis Investor Conference Presentations Now Available for On-Demand Viewing
Mon 05 Jul 21, 12:35 PMCannabis Industry Investor Presentations Now Available for On-Demand Viewing
Thu 01 Jul 21, 01:09 PMCannabis Industry Investor Conference: Company Executives Present June 29th & 30th
Tue 22 Jun 21, 12:35 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -72.45500M | -44.68100M | -36.67500M | -45.88400M | - |
| Minority interest | - | 0.00000M | - | 4.70M | 12.90M |
| Net income | -66.10100M | -45.63100M | -41.41400M | -48.13000M | - |
| Selling general administrative | 27.82M | 38.40M | 29.83M | 34.98M | - |
| Selling and marketing expenses | 1.90M | 3.80M | 2.58M | 3.18M | - |
| Gross profit | 4.33M | 6.81M | 7.41M | 3.10M | - |
| Reconciled depreciation | 3.67M | 3.51M | 3.59M | 1.48M | - |
| Ebit | -29.16000M | -38.69900M | -26.84600M | -36.54000M | -5.40800M |
| Ebitda | -25.69000M | -34.68900M | -24.70800M | -35.59400M | - |
| Depreciation and amortization | 3.47M | 4.01M | 2.14M | 0.95M | - |
| Non operating income net other | - | - | -7.09600M | - | - |
| Operating income | -29.16000M | -38.69900M | -26.84600M | -36.54000M | - |
| Other operating expenses | 46.96M | 54.07M | 38.96M | 44.37M | - |
| Interest expense | 2.70M | 6.82M | 4.46M | 2.68M | 0.00000M |
| Tax provision | -6.35400M | 0.95M | 0.00000M | 0.00000M | - |
| Interest income | - | - | - | - | - |
| Net interest income | -2.70200M | -6.81800M | -4.45500M | -2.68400M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | 1.68M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -6.35400M | 0.95M | 4.74M | 2.25M | -0.12600M |
| Total revenue | 17.80M | 15.37M | 12.12M | 7.83M | - |
| Total operating expenses | 33.49M | 45.51M | 34.26M | 39.64M | - |
| Cost of revenue | 13.47M | 8.56M | 4.70M | 4.73M | - |
| Total other income expense net | -43.29500M | -5.98200M | -9.82900M | -9.34400M | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -66.16500M | -45.72600M | -36.67500M | -45.98000M | - |
| Net income applicable to common shares | - | -45.72600M | -36.11400M | -39.53000M | 7.36M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 31.24M | 52.10M | 116.16M | 165.88M | 95.72M |
| Intangible assets | 2.65M | 3.35M | 23.12M | 24.28M | 25.51M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.55M | 3.15M | 0.47M | 3.53M | 4.44M |
| Total liab | 7.03M | 11.69M | 43.39M | 51.57M | 45.52M |
| Total stockholder equity | 24.22M | 40.41M | 72.77M | 114.31M | 45.50M |
| Deferred long term liab | - | - | - | 5.70M | - |
| Other current liab | 2.07M | 4.35M | 5.10M | 4.87M | 2.72M |
| Common stock | - | 3.36M | - | - | - |
| Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | -198.80400M | -180.90500M | -114.74000M | -79.79400M | -31.93300M |
| Other liab | - | - | 8.56M | 7.56M | 5.70M |
| Good will | - | - | 0.00000M | 18.51M | 20.19M |
| Other assets | 0.00000M | - | 0.26M | 0.05M | 0.00100M |
| Cash | 6.83M | 12.45M | 37.23M | 79.46M | 12.04M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.81M | 9.43M | 27.25M | 10.16M | 6.10M |
| Current deferred revenue | 0.02M | 1.07M | 0.65M | 0.87M | - |
| Net debt | -4.74400M | -8.59300M | -12.13100M | -45.61700M | 21.68M |
| Short term debt | 1.27M | 1.70M | 17.51M | - | - |
| Short long term debt | 0.50M | 0.47M | 17.51M | - | - |
| Short long term debt total | 2.09M | 3.86M | 25.09M | 33.84M | 33.73M |
| Other stockholder equity | 223.02M | 217.95M | 187.51M | 194.10M | 77.43M |
| Property plant equipment | - | - | 30.93M | 25.68M | 24.37M |
| Total current assets | 13.94M | 26.25M | 60.39M | 95.81M | 23.50M |
| Long term investments | 0.00000M | 5.68M | 1.46M | 1.55M | 2.08M |
| Net tangible assets | - | - | 49.65M | 52.46M | -0.20200M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.08M | 4.32M | 7.29M | 6.16M | 1.60M |
| Long term debt | 0.72M | 1.06M | 7.59M | 33.84M | 33.73M |
| Inventory | 4.48M | 8.40M | 15.41M | 10.19M | 5.42M |
| Accounts payable | 2.06M | 2.30M | 3.98M | 4.43M | 3.37M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -69.01400M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.50M | 6.70M | 0.26M | 0.05M | 0.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 17.30M | 25.85M | 55.77M | 70.07M | 72.22M |
| Capital lease obligations | 0.87M | 2.33M | - | - | - |
| Long term debt total | - | - | - | 33.84M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 1.19M | -7.28000M | -3.66500M | -1.79700M | 1.89M |
| Change to liabilities | - | -4.19700M | 6.00M | 3.79M | 1.69M |
| Total cashflows from investing activities | - | -7.28000M | -3.66500M | -33.90100M | -8.28100M |
| Net borrowings | - | 1.38M | 6.54M | 34.13M | 17.79M |
| Total cash from financing activities | 3.29M | 1.83M | 91.84M | 62.83M | 27.50M |
| Change to operating activities | - | -1.36800M | -0.11200M | -2.79000M | -1.30200M |
| Net income | -66.16500M | -45.72600M | -36.67500M | -45.98000M | 7.36M |
| Change in cash | -24.81100M | -41.76100M | 66.26M | -8.06500M | 15.07M |
| Begin period cash flow | 37.70M | 79.46M | 13.20M | 21.26M | - |
| End period cash flow | 12.89M | 37.70M | 79.46M | 13.20M | 21.26M |
| Total cash from operating activities | -29.06600M | -36.23300M | -21.96100M | -37.05200M | -4.27600M |
| Issuance of capital stock | 27.69M | 0.00000M | 18.02M | 28.57M | - |
| Depreciation | 3.67M | 3.51M | 3.59M | 1.48M | 0.10M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | 10.75M | - | - |
| Change to inventory | -4.45300M | -8.19800M | -4.77400M | -1.26500M | -0.24200M |
| Change to account receivables | -0.27800M | -0.54600M | -1.15000M | -0.52600M | -0.52600M |
| Sale purchase of stock | - | 0.00000M | -6.25000M | 0.00000M | - |
| Other cashflows from financing activities | -1.26600M | 28.37M | 95.01M | 34.88M | 73.13M |
| Change to netincome | - | 16.07M | 0.38M | 1.79M | -11.88500M |
| Capital expenditures | 1.31M | 7.28M | 3.67M | 18.68M | 4.47M |
| Change receivables | - | - | -1.38000M | - | - |
| Cash flows other operating | - | - | 10.83M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 66.21M | - | - |
| Change in working capital | -9.00000M | -14.30900M | -0.03700M | -0.79400M | - |
| Stock based compensation | 2.34M | 11.45M | 1.65M | 1.52M | - |
| Other non cash items | 46.73M | 7.89M | 3.85M | 0.55M | - |
| Free cash flow | -30.37200M | -43.51300M | -25.62600M | -55.72700M | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLVR Clever Leaves Holdings Inc |
- -% | 0.0001 | - | - | 0.0028 | 0.001 | 0.01 | -0.0676 |
| ZTS Zoetis Inc |
-0.7 0.58% | 119.79 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.09 0.35% | 25.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-3.634 2.72% | 130.15 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.09 0.49% | 18.12 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
Bodega 19-B, Parque Ind. Tibitoc P.H, Tocancipá, Colombia, 251017
| Name | Title | Year Born |
|---|---|---|
| Mr. Andres Fajardo | Co-Founder, CEO & Director | 1978 |
| Mr. Henry R. Hague III | Chief Financial Officer | 1972 |
| Mr. Gustavo Escobar | Chief Operating Officer | NA |
| Mr. David M. Kastin Esq. | Gen. Counsel & Corp. Sec. | 1968 |
| Diana Sigüenza | Strategic Communications Director | NA |
| Mr. Amit Pandey | Exec. VP of Fin. | 1982 |
| Mr. Julian Wilches | Chief Regulatory Officer | 1979 |
| Mr. Andrew Miller | Head of Bus. Devel. | NA |
| Mr. Camilo Bohorquez | Head of Colombia | NA |
| Ms. Caroline Kliess | Managing Director of Germany | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.